BioPharmSignal logoBioPharmSignal

Biotech News

Immix Biopharma to Participate in Upcoming Investor Conferences

Immix Biopharma (IMMX)Immix BiopharmaCompany update

LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences:

<li style="margin-top:0in;...

Related news

IMMXImmix Biopharma2026-08-04 14:15 EST

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

MMSIMerit Medical2026-08-05 16:00 EST

Merit Medical to Participate in Upcoming Investors Conferences in August

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

View all latest news

Immix Biopharma

Immix Biopharma is a biotechnology company focused on immune-driven therapies and oncology programs. Its strategy centers on translating immune biology into targeted treatment options.

Recent company news

IMMXImmix Biopharma2026-08-04 14:15 EST

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

IMMXImmix Biopharma2026-05-22 22:15 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-22 17:15 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-21 11:30 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-21 11:30 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

Stock data

Close
13.66 USD
Market cap
595.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States